全球医药业的盛会——世界制药原料展(CPhI)即将于今年10月在美丽的意大利米兰拉开帷幕。这一盛会已经成为全球医药界开展商贸交流和信息共享的重要平台。预计将吸引来自超过166个国家和地区的6.2万名参与者，展商数量超过2400家，势必再次掀起医药行业的热潮。

  龙8股份(Porton Pharma Solutions)作为全球领先的医药公司之一，将携技术专家团队和全球商务团队应邀出席此次展会。我们将与全球行业精英面对面，深入了解制药行业的最新动态和发展趋势，分享丰富的行业见解和产品开发经验，共同探讨产品创新，推动行业创新与高质量发展。

  为了更好地与行业同仁互动，龙8股份特别在第二天(10月9日)安排了两场在展位5C17的专业演讲活动。我们的两位技术专家将为您带来前沿的技术分享和行业洞见，其详细日程如下：

分享主题：

主题一：龙8斯洛文尼亚：推动CDMO行业创新，夯实全球化布局

  主题二：制粒工程在原料药和制剂研发中的应用

  此次分享活动将为您全面展示龙8股份在全球化步伐、技术研发和创新方面的最新成果，为您提供新视角和新思路，助力您在激烈的市场竞争中赢得先机。

  如您有兴趣参加我们在CPhI的展位活动，请提前安排行程前来交流。我们诚挚邀请您的光临，与我们一起探讨行业前沿动态，共同推动医药行业的高质量发展。

  期待与您相聚米兰，共同见证医药产业的美好未来!

Presenter Profile

SVP, Head of Global Chemical Engineering and Technology Center, Porton Pharma Solutions31-year experience in Pharma industry

Joined Porton JSTAR in 2014, previously served as the Head of Center for Pharma Crystallization, Dr. Jian Wang has over 30 years of process R&D experience specialized in API crystallization, reaction engineering, and PAT applications. Jian earned her Ph.D. in Chemical Engineering in 1994 from University of Pittsburgh, supervised by Prof. Donna Blackmond and Prof. Irving Winder. She has authored over 20 peer-reviewed articles and holds 6 patents, 5 on API crystallization.

From 1994 to 2005, Jian worked at Merck, addressing bottleneck process R&D issues via reaction engineering, API crystallization, and PAT application, as well as pilot plant process execution. She consulted at Mettler Toledo AutoChem from 2005-2010 and served as VP of Crystallization Development at Crystal Pharmatech from 2011-2013. Since 2014, she established a state-of-the-art crystallization center at J-STAR Research, working on API isolation challenges across developmental stages and integrating drug formulation services with API crystallization R&D.

Listening to clients’ needs, building up the team’s technical capabilities, and providing the right technical solutions have been Jian’s focus for decades. Her dedication and contributions to pharma process R&D have served broad needs of diverse global clients with technical rigor, synergy and efficiency.

R&D Director, Porton Pharmatech
15 years' experience in Pharma industry
Dr. Francesco Fontana graduated from the University of Milan and received a co-tutoring PhD degree from University of Milan and University P. et M. Curie (Paris) under the supervision of Prof. P. Dalla Croce and Prof. G. Poli, working on β-lactams preparation and transition metal catalysis in natural product synthesis.
In 2009, he conducted postdoctoral research at the University of Bristol on palladium-catalyzed reactions, in the field of carbonylation and carboxylation of vinyl-aziridines under the supervision of Prof. V. K. Aggarwal. In 2010, he joined FIS (Fabbrica Italiana Sintetici) as a process chemist developing, optimizing and scaling up processes for APIs and intermediates in the CDMO frame. He developed his career in FIS further as Team Leader in 2015 and R&D Manager in 2018 overseeing various R&D teams (flow chemistry team, process safety & process modelling team, troubleshooting & process improvement team), developing external collaborations and key-suppliers, and mentoring overseas company’s R&D teams (Delmar Inc., Canada).
In 2023, Dr. Francesco Fontana joined Porton Slovenia site (Porton Pharmatech), a newly European based R&D and manufacturing branch of Porton Pharma Solutions, as the R&D Director.
He is author of 25 peer-reviewed publications and patents.